tellmegen logo

ФАРМАКОЛОГИЧЕСКАЯ СОВМЕСТИМОСТЬ

Sulfonylurea metabolism

Sulfonylurea is an oral anti-diabetic drug (OAD). This group of medicines is commonly used to treat type 2 diabetes, an illness that affects close to 350 million persons worldwide. Genetic and non-genetic factors may influence how a person responds to these drugs. Persons with type 2 diabetes have chronically high blood sugar levels and sulfonylureas make the body free up more insulin (a hormone that activates the cells to absorb the sugar in the blood).

Sulfonylurea drugs are metabolized in the body using an enzyme called CYP2C9, which breaks up the drugs so that they can be filtered and eliminated from the body. The variations in the gene that encodes the CYP2C9 enzyme is associated with a reduced capacity to eliminate sulfonylurea from the body, leading to problems.

Contraindications

Sulfonylureas should not be administered to pregnant women, women who are breastfeeding, to diabetes mellitus type 1 patients, to children, to patients with diabetic ketoacidosis, with hyperosmolar nonketotic coma, with intercurrent diseases such as acute myocardial infarction, or cerebral vascular illnesses (stroke), nor whenever possible to patients who have advanced hepatic or renal insufficiency or who have porphyria.

GENE OR REGION STUDIED


  • CYP2C9

CYBER MONDAY

Лучшие сделки 2021 года

Используйте наши коды скидок Только до 30 ноября!

CYBER MONDAY

Используйте наши коды скидок

Только до 30 ноября!

КУПИТЬ